Solesence (NASDAQ:SLSN) Stock Price Up 2% - Time to Buy?

Solesence, Inc. (NASDAQ:SLSN - Get Free Report)'s share price shot up 2% during mid-day trading on Monday . The company traded as high as $1.55 and last traded at $1.54. 27,405 shares were traded during mid-day trading, a decline of 17% from the average session volume of 33,114 shares. The stock had previously closed at $1.51.Analysts Set New Price TargetsSeparately, Weiss Ratings reiterated a "sell (d)" rating on shares of Solesence in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Solesence currently has a consensus rating of "Sell".View Our Latest Stock Analysis on SolesenceSolesence Price PerformanceThe company has a market capitalization of $108.63 million, a P/E ratio of 154.15 and a beta of 1.08. The company has a quick ratio of 0.78, a current ratio of 1.84 and a debt-to-equity ratio of 0.61. The business has a 50 day simple moving average of $2.03 and a 200-day simple moving average of $3.07. Solesence (NASDAQ:SLSN - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.02) earnings per share for the quarter. The firm had revenue of $14.60 million during the quarter. Solesence had a return on equity of 6.53% and a net margin of 1.72%.Insider Activity at SolesenceIn other Solesence news, Director R Janet Whitmore purchased 19,789 shares of the business's stock in a transaction dated Friday, November 14th. The shares were bought at an average price of $1.73 per share, with a total value of $34,234.97. Following the completion of the acquisition, the director owned 2,068,931 shares in the company, valued at approximately $3,579,250.63. This represents a 0.97% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have purchased a total of 37,556 shares of company stock valued at $68,049 in the last quarter. 4.80% of the stock is currently owned by company insiders. Institutional Trading of SolesenceSeveral large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Solesence by 10.8% in the third quarter. Vanguard Group Inc. now owns 1,042,716 shares of the company's stock worth $3,358,000 after purchasing an additional 101,868 shares in the last quarter. Hunter Perkins Capital Management LLC acquired a new stake in Solesence in the second quarter worth about $1,909,000. Geode Capital Management LLC bought a new position in Solesence in the 2nd quarter valued at about $1,871,000. Kingsview Wealth Management LLC bought a new position in Solesence in the 2nd quarter valued at about $132,000. Finally, Modern Wealth Management LLC acquired a new position in Solesence during the 2nd quarter valued at about $119,000. 70.22% of the stock is currently owned by institutional investors and hedge funds. About Solesence (Get Free Report)Nanophase Technologies Corporation provides engineered materials, formulation development, and commercial manufacturing with an integrated family of technologies in the United States. It offers surface engineered zinc oxide and titanium dioxide for sunscreens and personal care products; fully formulated cosmetics, sun care, and skin care under the Solésence brand name; and advanced materials products, such as architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, medical diagnostics, and various surface finishing technologies applications.Featured ArticlesFive stocks we like better than SolesenceElon Taking SpaceX Public! $100 Pre-IPO Opportunity!How a Family Trust May Be Able To Help Preserve Your WealthA U.S. “birthright” claim worth trillions - activated quietlyTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyThis stock gets a 94 out of 100This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Solesence Right Now?Before you consider Solesence, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solesence wasn't on the list.While Solesence currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here